Evidence map›Paper›PMID 38166252›Full record

ReviewJournal of immunology (Baltimore, Md. : 1950)2024

Modulating Antigen Availability in Lymphoid Organs to Shape the Humoral Immune Response to Vaccines.

Aereas Aung, Darrell J Irvine

Abstract readReview
In one paragraph

Review in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aereas AungInstitute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0002-8637-1405

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR37AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty, Darrell J Irvine · 2021 to 2026
$5.4M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR01AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2016 to 2020
$4.3M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR33AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2024 to 2025
$3.2M
Immune engineering of optimized sequential immunization strategies for HIV vaccinesR33AI161297 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2024 to 2025
$2.5M
Immune engineering of optimized sequential immunization strategies for HIV vaccinesR61AI161297 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2021 to 2023
$2.3M
"Extended dosing" immunization to enhance humoral immunity to next-generation vaccinesR01AI175489 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Darrell J Irvine · 2023 to 2026
$1.9M
Howard Hughes Medical InstituteNIAID NIH HHS P01 AI048240NIAID NIH HHS R01 AI125068NIAID NIH HHS R01 AI175489NIAID NIH HHS R33 AI161297NIAID NIH HHS R33 AI161818NIAID NIH HHS R37 AI125068NIAID NIH HHS R61 AI161297NIAID NIH HHS R61 AI161818NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Primary immune responses following vaccination are initiated in draining lymph nodes, where naive T and B cells encounter Ag and undergo coordinated steps of activation. For humoral immunity, the amount of Ag present over time, its localization to follicles and follicular dendritic cells, and the Ag's structural state all play important roles in determining the subsequent immune response. Recent studies have shown that multiple elements of vaccine design can impact Ag availability in lymphoid tissues, including the choice of adjuvant, physical form of the immunogen, and dosing kinetics. These vaccine design elements affect the transport of Ag to lymph nodes, Ag's localization in the tissue, the duration of Ag availability, and the structural integrity of the Ag. In this review, we discuss these findings and their implications for engineering more effective vaccines, particularly for difficult to neutralize pathogens.

Indexed as

Immunity, HumoralVaccinesAntigensLymph NodesVaccinationAntigensVaccines

Identifiers

PMID38166252
PMCPMC10768795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.